TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with multiple sclerosis for at least 6 months~* Neurogenic detrusor overactivity without DSD~* Symptoms of OAB~* Patients capable of completing the bladder diary~* Patients capable of independent toileting~* Patients able to swallow the study medication in accordance to the protocol~* Body Mass Index \>/= 18,8 kg/qm and \</= 35,0 kg/qm~* documented, dated, written informed consent~Exclusion Criteria:~* Treatment with drugs known to affect mainly the urinary function 14 days prior to starting completion of the baseline diary for Visit 2~* Participation in a bladder-training program~* Low compliance bladder (Compliance \<20 mL/cm H2O)~* DSD, Detrusor hyporeflexia / areflexia and bradykinesia / tremor of the external urethral sphincter~* Indwelling catheter or intermittent self-catheterization~* Patience with post-void residual (PVR) urinary volume \> 200 mL at baseline~* Urinary retention or clinically significant bladder outlet obstruction as detected by the investigator~* Clinically predominant and bothersome stress urinary incontinence~* Neurological diseases other than multiple sclerosis affecting urinary bladder function~* Any urogenital surgery within 12 month prior to Visit 1~* 17 Additional Exclusion Criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AS: Ankle Spacer for Talar Osteochondral Defects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age ranging from 18 to 80 years~* talar osteochondral defect (multiple degenerative talar cysts present, and/or prior failed surgical treatment and/or multiple defects and/or large (\>15mm))~* willing to receive surgical implantation of the Ankle Spacer~* has been informed of the nature of the study and provided written consent~* The subject and treating physician agree that the subject will return for all required post-procedure follow-up visits~* failed previous conservative treatment~* complaints for at least 6 months~Exclusion Criteria:~* -severe ankle malalignement.(\> 5° varus/valgus).~* fracture \< 6 months - tendinitis - diabetes mellitus / rheumathoid arthritis~* advanced osteoporosis~* grade two or higher (Kellgren-Lawrence-Score) ankle joint degeneration on the tibia side.~* any ankle deformation that does not allow proper rasping of the cartilage and/or proper seating of the desired sized implant, as described in the surgical technique.~* blood supply limitations and previous infections, which may retard healing.~* foreign-body sensitivity. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation.~* active infection or blood supply limitations.~* conditions that tend to limit the patient's ability or willingness to restrict activities or follow directions during the healing period, including severe neuro-arthropathy.~* pathological conditions, such as insufficient quantity or quality of bone (e.g., cystic changes or severe osteopenia), which may compromise implant fixation.~* currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.~* Inability to be brought back to the surgery site for long term follow-up evaluations or the subject is unwilling to fill out the appropriate evaluation forms~* adiposity grade I (BMI \> 30 kg/m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ankle Spacer (AS) (Type: EXPERIMENTAL): This arm will surgically receive the to be implanted ankle spacer in their ankle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age group between 45 and 65 at the time of informed consent.~* Physician diagnosis of menopause.~* History of substantial hot flashes \> 4 episodes /day for last 2 weeks.~* Being post-menopausal with an intact uterus.~* Subject has provided signed and dated written informed consent before admission to the study.~Exclusion Criteria:~* Concurrent hot flash therapies (prescription medications including hormone replacement therapies, gabapentin or over the counter supplements), vaginal hormonal products (rings, creams, gels) or transdermal estrogen or estrogen/progestin products for 30 days before screening visit.~* Women currently or previously on anticoagulants, Vitamin K antagonists like warfarin in the past 3 months, or expected to be on anticoagulants in the near future.~* Women involved in other clinical studies within the last 30 days.~* Any women who, in the opinion of the principal investigator, is at poor medical or psychiatric risk for the study.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): all natural dietary supplement
- Treatment + Omega-3s (Type: OTHER): all natural dietary supplement + omega-3s
- Placebo (Type: PLACEBO_COMPARATOR): vegetable oil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cryoneurolysis of Arnold's Nerve and Follow-up by Tractography: Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 18 and over~* Patient with cephalalgic syndrome\> 3 months,~* Patient with an indication of first cryoneurolysis~* Unilateral character of cephalalgic syndrome~* Failure of oral treatment of stage II~* Positive response (\> 50% efficacy on pain EVA) to infiltration of Arnold's nerve~* Subject having signed his written participation consent~Exclusion Criteria:~* Coagulation disorder~* Infection in progress~* Patient under anticoagulant~* Contraindication to performing an MRI:~  1. Any subject with a vascular stent implanted less than 6 weeks before the examination.~ 2. Any subject with implanted biomedical material deemed unsafe or unsafe in the list: http://www.mrisafety.com/TheList_search.asp.~ 3. Any acquisition procedure that does not meet the conditions required for conditional use in a subject carrying implanted biomedical material deemed conditional in the list: http://www.mrisafety.com/TheList_search.asp.~ 4. Any subject carrying an intra-ocular or intra-cranial ferromagnetic foreign body close to the nerve structures.~ 5. Any subject carrying a biomedical material such as a cardiac, neuronal or sensory stimulator (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects.~ 6. Non-cooperating subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- neuralgic patients (Type: EXPERIMENTAL): MRI experimentation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.~* Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:.~  i) Autologous stem cell transplant (ASCT) ineligible patients.~ii) Patients after failure of ASCT.~- Must have at least one lesion that is \> 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.~Exclusion Criteria~* Known central nervous system lymphoma.~* Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).~* Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).~* Other protocol-defined Inclusion/Exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Module A (Type: EXPERIMENTAL): Nivolumab combined with Brentuximab
- Module B (Type: EXPERIMENTAL): Brentuximab alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled to undergo robotic prostatectomy.~* Patients undergoing peritoneal tumor debulking and chemotherapy~* Mechanically ventilated Burn Intensive Care Unit (BICU) Patients~* Mechanically ventilated Neuro Care Unit (NCU) Patients who have suffered a stroke~Exclusion Criteria:~* ICU patients who are not receiving enteral feeds~* Patients who present for tumor debulking or robotic prostatectomy who receive preoperative H2 blockers, proton pump inhibitors, antacids or metoclopramide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- supraglottic impendence/pH probe (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy. (TORSIV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged between 18 and 80, who will undergo bronchoscopy~* FEV1≥ 50% of theorical value~* Ambient air saturation at rest ≥ 94%~* No allergy to midazolam, to hydroxyzine, Lidocaine (used for local anesthesia) or one of their compound~* fasting for at least 6 hours~* No indication against bronchoscopy, nor to premedication~* Informed consent signed~Exclusion Criteria:~* Pregnant or lactating, women~* PAH patients~* patients undergoing bronchoscopy with bronchoalveolar lavage and / or trans-bronchial biopsy~* Patients with oral anticoagulants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- I.V. sedation (Type: EXPERIMENTAL): Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
- sublingual sedation (Type: ACTIVE_COMPARATOR): Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Early Integration of Palliative Care in Esophageal Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients newly diagnosed or referred to the Esophageal Diagnostic Assessment Program (EDAP) program with suspicious findings found to be esophageal cancer AND~* Patients who present with metastatic disease, defined as N3 lymph node involvement or distant metastatic deposits as confirmed on PET scan~* Patients must have been notified by a member of their healthcare team of their prognosis and palliative categorization as noted in the patient chart within 8 weeks of diagnosis~* Patients may undergo esophagectomy, stenting, brachytherapy or palliative intent chemotherapy or radiotherapy as clinically indicated~Exclusion Criteria:~* Individuals unable to complete questionnaires with assistance~* Patients presently undergoing neoadjuvant chemotherapy or radiotherapy for malignancy~* Patients with recurrent esophageal cancer~* Patients who are referred back to EDAP for restaging after completing neoadjuvant therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Palliative Care Group (Type: EXPERIMENTAL): This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient ≥ 30 years old~* Written informed consent obtained~* Patient with Body mass index (BMI) ≥ 20~* Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study~* COPD patient with GOLD stages C and D~* Patient with a Borg Fatigue score after the 6MWT on screening above 4 to indicate the susceptibility to dynamics hyperinflation~* Patient with smoking history of at least 10 pack-years~* Patient takes a combination therapy of LABA/ LAMA at least 6 weeks before visit 1~* Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions~Exclusion Criteria:~* Pregnant or lactating females~* Patient with severe immunological diseases and/ or severe acute infectious diseases~* Patient with heart failure as documented in the medical history or as defined by the investigator during the physical examination performed at visit 1~* Patient with diagnosis of cancer (except basal cell carcinoma)~* Patient with a history of depression associated with suicidal ideation or behaviour~* Patient with moderate or severe hepatic impairment.~* Patient with lactose intolerance~* Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.~* Patient who received inhalation corticosteroids (ICS) within the last 6 weeks prior to the screening visit~* Patient who received any investigational new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be seen at the St. Louis Children's Hospital NF Clinic~* Diagnosis of NF1~* Between 1 and 7 years of age, inclusive~* Diagnosed with hypotonia~* Legally authorized representative/guardian must be able to understand and willing to sign an IRB-approved informed consent document~* Must have an MRI scan ordered by a treating physician~Exclusion Criteria:~* Normal tone on clinical exam~* Known allergy to gadolinium or the sedative, propofol, used during MRI~* Poor kidney function defined as a known renal disease or elevated BUN and creatine~* Requiring intubation for anesthesia

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: MRI of brain with gadolinium contrast (Type: EXPERIMENTAL): -Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Montelukast Added to Standard Therapy for Acute Asthma in Children Age 6-14 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Seeking care in ED for acute asthma exacerbation~* Age 6-14 years inclusive~* Initial FEV1 = 40-70% predicted (defined as moderate severity)~* Consent to participate in study~Exclusion Criteria:~* Severe exacerbation requiring immediate therapy as determined by treating clinician~* Pregnancy by history~* Cystic Fibrosis by history~* Tuberculosis~* Gastroesophageal reflux disease requiring medications~* Acute or chronic liver disease~* Bronchopulmonary dysplasia~* Premature \<34 weeks gestational age by history~* Having used leukotriene-modifying medication within 48 hours~* Having used theophylline within four weeks~* Unable to perform FEV1

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with NFD/NSF following a kidney transplant~* diagnosed with NFD/NSF following a liver transplant~* NFD/NSF and who have not had a kidney or liver transplant~* diagnosed with NFD/NSF and who have not had a kidney or liver transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): One to three 5-day course of plasma exchange (plasmapheresis)
- Group 2 (Type: ACTIVE_COMPARATOR): One to three 5-day course of plasma exchange (plasmapheresis)
- Group 3 (Type: NO_INTERVENTION): No intervention taken
- Group 4 (Type: ACTIVE_COMPARATOR): One to three 5-day course of plasma exchange (plasmapheresis)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vertebral Body Tethering Treatment for Idiopathic Scoliosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females age 8 to 16 years old at time of enrollment (inclusive)~2. Diagnosis of idiopathic scoliosis~3. Sanders bone age of less than or equal to 4~4. Thoracic or thoracolumbar/lumbar curves of greater than or equal to 35 degrees and less than or equal to 60 degrees from levels T4 through L3~5. Lenke classification of 1, 2, 3, 5, or 6~6. Patient has already been identified for and recommended to have surgical intervention~7. Spina bifida occulta is permitted~8. Spondylolysis or Spondylolisthesis is permitted, as long as it is non-operative, the patient has not had any previous surgery for this, and no surgery is planned in the future~9. Completed standard-of-care procedures as outlined in Section 5~Exclusion Criteria:~1. Pregnancy (current)~2. Prior spinal or chest surgery~3. MRI abnormalities (including syrinx greater than 4mm, Chiari malformation, or tethered cord)~4. Neuromuscular, thoracogenic, cardiogenic scoliosis, or any other non-idiopathic scoliosis~5. Associated syndrome, including Marfan Disease or Neurofibromatosis~6. Sanders bone age greater than 4~7. Thoracic or thoracolumbar/lumbar curves less than 35 degrees or greater than 60 degrees~8. Compensatory curve greater than 35 degrees without intent to treat surgically~9. Unable or unwilling to firmly commit to returning for required follow-up visits~10. Investigator judgement that the subject/family may not be a candidate for the intervention

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Anterior Vertebral Body Tethering (Type: EXPERIMENTAL): Subjects who will be undergoing the anterior vertebral body tethering surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy